Lattice Biologics Closes Fifth Tranche of Private Placement and Extends Funding Raise for an Additional 30 Days

About this update from Lattice Biologics Ltd

Lattice Biologics Closes Fifth Tranche of Private Placement and Extends Funding Raise for an Additional 30 Days Lattice Biologics Closes Fifth Tranche of Private Placement and Extends Funding Raise for an Additional 30 Days SCOTTSDALE, AZ--(Marketwired - April 04, 2017) - NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the fifth tranche of its non-brokered private placement of Units of the Company ("Units") announced on January 19, 2017 (the "Private Placement"). The Company has also extended the Private Placement for a period of 30 days.Pursuant to the fifth tranche of the Private Placement, Lattice Biologics has issued 334,540 Units at a price of Can$0.20 per Unit, representing gross proceeds of US$50,000. Each Unit consists of one common share in the capital stock of the Company (a "Common Share") and one-half of one non-transferable common share purchase warrant (a "Warrant"). Each whole Warrant is exercisable into an additional Common Share at a price of Can$0.265 per Common Share for a period of 36 months from the date of closing the Private Placement.The Common Shares, and any Common Shares issuable upon exercise of the Warrants will be subject to a hold period expiring on August 4, 2017.This latest tranche brings the total investor funding raised as part of the Private Placement (including amounts announced on January 24, 2017, January 26, 2017, February 16, 2017 and February 28, 2017) to US$370,000.Lattice Biologics has received conditional approval for the Offering from the TSX Venture Exchange.The net proceeds from the Private Placement will be used for general working capital, including to support increasing production of Lattice Biologics' recently launched minimally processed amniotic fluid supplement for the treatment of joint pain associated with osteoarthritis. Lattice Biologics Ltd.Guy Cook,Chief Executive OfficerTelephone No: (480) 563-0800About Lattice Biologics Ltd.:Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.Versatile a...

View stock analysis, news, and events for Lattice Biologics Ltd